1. Participant is ≥18 years of age, at the time of signing the informed consent. 2. Participant has laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcriptase polymerase chain reaction (RT-PCR) or other approved clinical testing prior to randomization. 3. Participant is hospitalized in relation to COVID-19, requiring supplemental oxygen to maintain SpO2 at a safe level (WHO level 4). 4. Participant is male or female. All females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study. (Females who are not of childbearing potential do not need to undergo a pregnancy test at screening). 5. Participant is capable of giving signed informed consent as described in the protocol.

1. Participant is ≥18 years of age, at the time of signing the informed consent. 2. Participant has laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcriptase polymerase chain reaction (RT-PCR) or other approved clinical testing prior to randomization. 3. Participant is hospitalized in relation to COVID-19, requiring supplemental oxygen to maintain SpO2 at a safe level (WHO level 4). 4. Participant is male or female. All females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study. (Females who are not of childbearing potential do not need to undergo a pregnancy test at screening). 5. Participant is capable of giving signed informed consent as described in the protocol.